Novo unveils twelve more GLP-1 and amylin launches through 2030 as 2032 patent cliff looms
The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.
The Scientist · Science desk
What happened
- At its capital markets day in London, CEO Mike Doustdar said Novo would launch at least five multi-blockbusters by 2030 and grow revenue on par with other major pharma companies.
- Those launches are meant to come from more than five Phase III programs in obesity and diabetes, plus another five or more Phase III programs in other therapeutic areas.
- Novo's primary shares fell from DKK 281.55 to DKK 260.00 in Copenhagen that morning, with the New York depositary receipts down from $43.24 to $39.81.
- In a research note, BMO Capital Markets' Evan Seigerman called the 2026-2030 revenue growth target in line with industry peers and likely underwhelming for investors.
Why it matters
- What it limits constraint Every product Novo dated for 2027 through 2030 except two is a GLP-1 or amylin agent, so the non-metabolic programs cannot reach patients in time to cushion the 2032 semaglutide cliff.
- Who has to decide decision Doustdar said Novo "will be more active within business development." Business development is the only lever he named, so the diversification rests on deals not yet signed, and Novo has just told counterparties it expects peer-level growth.
- Who's exposed exposure Holders who bought Novo for a GLP-1 franchise are now being asked to underwrite a probability-weighted 2035 sales total instead, with the 2032 exclusivity answer still outstanding.
- What doesn't add up contradiction Union Investment's Manns faulted Novo for saying little about the patent expiry yet called its case for next-generation obesity drugs credible, so investors were selling the missing cliff plan, not the drug class.
Next story · Product · Oct 6
Novo says biological age fell two to three years on its GLP-1 drug; Lilly reports similar slowing effectConfirmed2 publishers
Novo's published launch calendar names fourteen products for 2027 through 2030. Once-weekly CagriSema, the amylin receptor agonist cagrilintide paired with semaglutide, is first, next year [19]. Cagrilintide on its own and a high-dose CagriSema follow in 2028 [20]. The 2029 slate is high-dose cagrilintide, zenagamtide (a peptide agonist at the GLP-1, amylin and calcitonin receptors), an oral zenagamtide and a next-generation GLP-1 [21]. For 2030 the company listed a monthly GLP-1, a thermostable GLP-1, an oral high-yield GLP-1, the long-acting amylin analogue Amylin 355 and an oral version of it, the oral ACSL5 inhibitor LX9851 co-developed with Lexicon Pharmaceuticals, and the triple agonist UBT251 [22]. Twelve of the fourteen are GLP-1 agents, amylin agents, or both; LX9851 and UBT251 are the two that are not [23].
The programs Novo counted outside diabetes and obesity all sit behind that calendar [2]. Novo put a number on the pipeline as a whole: more than DKK 150bn of risk-adjusted sales by 2035, a figure that includes assets already in the pipeline [8]. That total is probability-weighted and a decade out, so it does not measure how much of Novo's future lies outside metabolic disease. The only quantity attached to that part of the plan is a count of Phase III programs, five or more [2].
The slide began while Doustdar was still speaking. STAT reported the shares down 5% during his opening remarks [7]. Per Hansen, investment economist at Nordnet, wrote in a research note reported by Bloomberg News that "Investors are selling the shares because they are not seeing concrete news that could drive the stock higher" [14]. On CNBC, Hansen said: "Investors hoped for a project 'miracle' that could turn the momentum around short term. For obvious reasons that miracle does not exist." [15]
Seigerman's note cited consensus estimates of 3.53% compound annual growth for Novo against about 3.65% for its pharma peers [10], a gap of 0.12 percentage points [24]. He wrote that the growth expectation Novo outlined already appeared priced in to Wall Street estimates, and that it read negatively for the shares [11].
Doustdar called the 2032 loss of US exclusivity for semaglutide, sold as Ozempic for type 2 diabetes and as Wegovy for obesity and weight control, "the elephant in the room" [12]. He said Novo planned to come out the other side of the LOE as a bigger company than it is today, and a much more diversified one [13]. Markus Manns, a portfolio manager at Union Investment, told Reuters: "They (also) did not say much in terms of how to tackle the semaglutide patent expiration in 2032" [17]. Manns also said he was less than impressed by Novo's 2030 sales projections and a "broadly stable" operating margin [16].
What to watch
- Whether Novo's promised business-development activity puts a non-metabolic asset into late-stage development before 2032.
- Any split of the DKK 150bn risk-adjusted 2035 figure by therapy area at a later results presentation.
- Whether the 2027 CagriSema launch and the 2029 oral zenagamtide date hold, since ten of the fourteen listed products arrive in 2029 and 2030.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence64
- Adoption34
- Hype gap+24
- Incentives80
- Confidence67
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
At Novo Nordisk's capital markets day in London on Monday, CEO Mike Doustdar said Novo would launch at least five multi-blockbusters by 2030 and deliver revenue growth on par with other major pharma firms.
- [2]
Novo said the five multi-blockbusters are expected to emerge from more than five Phase III programs in obesity and diabetes, and another 5+ Phase III programs in other therapeutic areas.
- [3]
Novo plans to combine internal pipeline growth with external growth through merger-and-acquisition activity.
- [4]
Doustdar said the company "will be more active within business development," an acknowledgment of investors' concerns that Novo was too reliant on its GLP-1 drugs.
- [5]
Novo's primary shares on Nasdaq Copenhagen slumped nearly 8% in the morning, from DKK 281.55 to DKK 260.00.
- [6]
Novo's American depositary receipts on the New York Stock Exchange fell 8%, from $43.24 to $39.81.
- [7]
Novo shares dropped 5% during Doustdar's opening remarks, a sign that investors wanted more specifics.
- [8]
Doustdar committed Novo to generating more than DKK 150 billion in risk-adjusted pipeline sales by 2035, a figure that includes current pipeline assets.
- [9]
Evan David Seigerman, managing director and head of healthcare research at BMO Capital Markets, wrote in a research note: "Novo is targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors."
- [10]
Seigerman cited a consensus of analysts that estimates a 3.53% compound annual growth rate for Novo, versus about 3.65% CAGR for its pharma peers.
- [11]
Seigerman wrote: "Novo's outlined growth expectation appears already priced in to [Wall] Street estimates, reading negatively to shares."
- [12]
Doustdar said planning for the eventual loss of U.S. patent exclusivity in 2032 for semaglutide, marketed as Ozempic for type 2 diabetes in adults and as Wegovy for obesity and weight control, was key to the new strategy, and called it "the elephant in the room."
- [13]
Doustdar said: "We plan to come on the other side of the LOE [loss of exclusivity] as a bigger company than we are today and a much more diversified version of it."
- [14]
Per Hansen, investment economist at Nordnet, wrote in a research note reported by Bloomberg News: "Investors are selling the shares because they are not seeing concrete news that could drive the stock higher."
- [15]
Speaking on CNBC, Hansen said: "Investors hoped for a project 'miracle' that could turn the momentum around short term. For obvious reasons that miracle does not exist."
- [16]
Markus Manns, a portfolio manager at Union Investment, told Reuters he was less than impressed by Novo's projections of 2030 sales and a "broadly stable" operating margin.
- [17]
Manns said: "They (also) did not say much in terms of how to tackle the semaglutide patent expiration in 2032."
- [18]
Manns said he thought Novo made a credible case for pursuing next-generation obesity drugs and a broader early-stage pipeline.
- [19]
Novo plans to launch once-weekly CagriSema, combining the long-acting amylin receptor agonist cagrilintide with the GLP-1 receptor agonist semaglutide, next year for diabetes and obesity.
- [20]
Cagrilintide and a high-dose version of CagriSema are scheduled for a 2028 launch.
- [21]
Novo's 2029 launches are expected to be high-dose cagrilintide; zenagamtide, a multi-receptor peptide agonist targeting GLP-1, amylin and calcitonin receptors; an oral form of zenagamtide; and a next-generation GLP-1.
- [22]
Novo's 2030 launch calendar includes a monthly-dose GLP-1, a thermostable GLP-1, an oral high-yield GLP-1, Amylin 355 and an oral version, both long-acting amylin analogues, the oral ACSL5 inhibitor LX9851 co-developed with Lexicon Pharmaceuticals, and UBT251, a long-acting synthetic peptide triple agonist.
- [23]
Of the fourteen products Novo named for launch between 2027 and 2030, twelve are described as GLP-1 agents, amylin agents, or both; the exceptions are the ACSL5 inhibitor LX9851 and the triple agonist UBT251.
- [24]
The consensus growth rate cited for Novo is 0.12 percentage points below the figure cited for its pharma peers.
Sources
2 independent publishers whose own reporting we read for this story.
- genengnews.comStockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day
1 article · September 21, 2026
- statnews.comSTAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
2 articles · September 21, 2026
Topics and entities
Topics
- Investor day guidance
- GLP-1 drugs
- Drug pipeline strategy
- Obesity Therapeutics
- Loss of exclusivity
Entities
- Eli Lilly
- Semaglutide
- Tirzepatide
- United Biotechnology
- Lexicon Pharmaceuticals
- Evan David Seigerman
- Novo Nordisk
- Union Investment
- BMO Capital Markets